MedTrace Logo

rhPTH Therapy for Low Turnover Bone Fragility

NCT00145886 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2016-01-12

No results posted yet for this study

Summary

The purpose of this study is to determine how treatment with a new medication, recombinant human parathyroid hormone (rhPTH) affects calcium balance and bone strength.

Conditions

  • Osteopetrosis

Interventions

DRUG

rhPTH

Subjects will be treated with rhPTH for 12 months.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Tamara Vokes, MD · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00145886 on ClinicalTrials.gov